Roivant Sciences Ltd. (ROIV)
| Market Cap | 20.44B +166.7% |
| Revenue (ttm) | 13.31M -56.4% |
| Net Income | -809.24M |
| EPS | -1.17 |
| Shares Out | 715.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,604,831 |
| Open | 28.36 |
| Previous Close | 28.28 |
| Day's Range | 28.17 - 28.90 |
| 52-Week Range | 10.58 - 30.33 |
| Beta | 1.14 |
| Analysts | Strong Buy |
| Price Target | 28.94 (+1.33%) |
| Earnings Date | May 28, 2026 |
About ROIV
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monocl... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ROIV stock is "Strong Buy." The 12-month stock price target is $28.94, which is an increase of 1.33% from the latest price.
News
Roivant Sciences participates in a conference call with JPMorgan
Conference call with management will be held on April 22 at 12 pm hosted by JPMorgan.
Roivant Sciences assumed with an Overweight at Piper Sandler
Piper Sandler assumed coverage of Roivant Sciences (ROIV) with an Overweight rating with a price target of $40, up from $22. The firm notes Roivant has traded up about 190%-plus
Roivant Sciences price target raised to $34 from $30 at Jefferies
Jefferies analyst Dennis Ding raised the firm’s price target on Roivant Sciences (ROIV) to $34 from $30 and keeps a Buy rating on the shares. A key question post the
Roivant Sciences Transcript: Study result
A new combined phase II-B/III trial for brepocitinib in lichen planopilaris has begun, targeting a severe, high-unmet-need scalp disorder with no approved therapies. The phase III TED study for batoclimab did not meet its primary endpoint, but data support ongoing Graves’ disease programs with next-generation FcRn inhibitors.
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA...
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA...
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
DURHAM, N.C., March 28, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics, a clinical-stage biotechnology company focused on developing targeted therapeutics in autoimmune disease, announced today the pu...
Bernstein bullish on Roivant Sciences, initiates with an Outperform
As previously reported, Bernstein initiated coverage of Roivant Sciences (ROIV) with an Outperform rating and $35 price target The firm sees upside into upcoming readouts in Pulmonary Hypertension ass...
Roivant Sciences initiated with an Outperform at Bernstein
Bernstein analyst William Pickering initiated coverage of Roivant Sciences (ROIV) with an Outperform rating and $35 price target
Roivant Sciences Transcript: Leerink Global Healthcare Conference 2026
A transformative period is underway with the launch of brepocitinib for dermatomyositis expected by end of Q3, supported by a robust pipeline including NIU, cutaneous sarcoidosis, and mosliciguat for PH-ILD. Additional FcRn inhibitor data and a major Graves' disease readout are anticipated.
Roivant Sciences price target raised to $33 from $31 at JPMorgan
JPMorgan raised the firm’s price target on Roivant Sciences (ROIV) to $33 from $31 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect
Moderna resolves litigation with Arbutus, to pay up to $2.25B in settlement
As previously reported, Moderna (MRNA) announced that it has entered into a settlement agreement with Arbutus Biopharma (ABUS) and Genevant Sciences, a subsidiary of Roivant Sciences (ROIV), resolving...
Roivant Sciences price target raised to $29 from $26 at BofA
BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $29 from $26 and keeps a Neutral rating on the shares after the company announced a
Roivant Sciences price target raised to $34 from $33 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Roivant Sciences (ROIV) to $34 from $33 and keeps a Buy rating on the shares. The firm added the company’s $2.25B in
Roivant Sciences Transcript: Status update
A $2.25 billion global settlement with Moderna resolves all COVID-19 vaccine patent litigation, including a $950 million upfront payment and a $1.3 billion contingent on appeal. Proceeds will fund pipeline investments and a $1 billion share buyback, while Pfizer-BioNTech litigation continues.
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences , and Arbutus Biopharma up to $2.25 billion to settle a long-running legal fight over the technology that made its ...
Genevant, Arbutus announce $2.25B global settlement with Moderna
Genevant Sciences, a subsidiary of Roivant Sciences (ROIV), and Arbutus Biopharma Corporation (ABUS), announced that they have entered into a $2.25 billion global settlement with Moderna (MRNA) to res...
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,...
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,...
Roivant Sciences Transcript: TD Cowen 46th Annual Health Care Conference
Priority review accelerates a key therapy’s launch to September, with broad label ambitions and strong physician enthusiasm for steroid-sparing benefits. Multiple late-stage trials in NIU, cutaneous sarcoidosis, PH-ILD, and Graves’ disease are progressing, with pivotal data expected this year and next.
Roivant Sciences announces U.S. FDA accepted its NDA for brepocitinib
Priovant Therapeutics announced that the U.S. Food and Drug Administration, FDA, has accepted its New Drug Application, NDA, for brepocitinib for the treatment of dermatomyositis, DM, and has granted ...
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026 Priority Review supported by positive Phase 3 VALOR results, the first...
Roivant Sciences price target raised to $35 from $26 at Citi
Citi raised the firm’s price target on Roivant Sciences (ROIV) to $35 from $26 and keeps a Buy rating on the shares. The firm views the company’s Phase 2 data
Roivant Sciences price target raised to $33 from $26 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Roivant Sciences (ROIV) to $33 from $26 and keeps a Buy rating on the shares. The firm says the company reported “impressive”
Roivant Sciences price target raised to $26 from $22 at BofA
BofA raised the firm’s price target on Roivant Sciences (ROIV) to $26 from $22 and keeps a Neutral rating on the shares. The fiscal Q3 print was in-line and the